Identification of the Cortical Neurons that Mediate Antidepressant Responses  by Schmidt, Eric F. et al.
Identification of the Cortical Neurons
that Mediate Antidepressant Responses
Eric F. Schmidt,1 Jennifer L. Warner-Schmidt,2 Benjamin G. Otopalik,1 Sarah B. Pickett,1 Paul Greengard,2
and Nathaniel Heintz1,*
1Laboratory of Molecular Biology, Howard Hughes Medical Institute
2Laboratory of Molecular and Cellular Neuroscience
The Rockefeller University, 1230 York Ave., New York, NY 10065, USA
*Correspondence: heintz@rockefeller.edu
DOI 10.1016/j.cell.2012.03.038SUMMARY
Our understanding of current treatments for depres-
sion, and the development of more specific thera-
pies, is limited by the complexity of the circuits
controlling mood and the distributed actions of anti-
depressants. Although the therapeutic efficacy of
serotonin-specific reuptake inhibitors (SSRIs) is
correlated with increases in cortical activity, the cell
types crucial for their action remain unknown. Here
we employ bacTRAP translational profiling to show
that layer 5 corticostriatal pyramidal cells expressing
p11 (S100a10) are strongly and specifically respon-
sive to chronic antidepressant treatment. This
response requires p11 and includes the specific
induction of Htr4 expression. Cortex-specific dele-
tion of p11 abolishes behavioral responses to SSRIs,
but does not lead to increased depression-like
behaviors. Our data identify corticostriatal projection
neurons as critical for the response to antidepres-
sants, and suggest that the regulation of seroto-
nergic tone in this single cell type plays a pivotal
role in antidepressant therapy.
INTRODUCTION
Mood is governed by the actions of a complex, anatomically
dispersed circuit comprised of specific subpopulations of
neurons arranged into functional units. Functional imaging
studies of patients suffering from major depressive disorder
(MDD), bipolar disorder, and anxiety indicate that a fundamental
neural circuit controls emotion, with different elements of the
circuit contributing to specific aspects of emotive behavior
(Drevets et al., 2008; Mayberg, 2009). For example, fMRI and
PET imaging of patients suffering from MDD has consistently
demonstrated decreased prefrontal cortex function, and
alterations in the activity of subcortical structures that include
the basal ganglia, amygdala, and thalamus (Drevets, 2000;
Mayberg et al., 1999). There is general agreement that in MDD,
disease and treatment mechanisms impact the same basic
circuitry controlling emotional state. However, it is evident from1152 Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc.deep brain stimulation studies in a number of neurological
and psychiatric disorders that the pathological mechanisms
causing dysfunction and the immediate targets of clinical
interventions most effective in alleviating symptoms may involve
different brain structures. Given this realization, our under-
standing of the pathophysiology of depression as well as
the development of improved therapies for this disorder will
be advanced by identification of cell types and molecular
mechanisms responsible for generating depression-like pheno-
types, as well as those mediating responses to antidepressant
treatment.
Recently, p11 (the protein product of the S100a10 gene) was
found to be an important factor mediating antidepressant
responses and depression-like states (Svenningsson et al.,
2006). P11 is an adaptor protein that is expressed specifically
in the central nervous system (CNS) (Egeland et al., 2011). It
regulates serotonin signaling by binding to serotonin receptors
(Htrs) 1b, 1d, and 4 and stabilizing the localization of these
receptors at the cell surface (Svenningsson et al., 2006;
Warner-Schmidt et al., 2009). Decreased p11 levels were found
in the cortex of MDD patients, suicide victims, and a mouse
model of depression (Anisman et al., 2008; Svenningsson
et al., 2006). Chronic antidepressant treatment, electroconvul-
sive therapy, and brain-derived neurotrophic factor treatment
all result in increased p11 expression in the cerebral cortex
(Svenningsson et al., 2006; Warner-Schmidt et al., 2010).
Importantly, mice lacking p11 exhibit depressive-like behaviors,
increased anxiety, and a blunted behavioral response to
antidepressant treatment (Svenningsson et al., 2006; Warner-
Schmidt et al., 2009).
Antidepressant drugs target neuromodulatory systems that
have widespread effects throughout the CNS, engaging recep-
tors that are broadly expressed in the brain. Although the
pharmacological effect of these drugs is immediate, there is
a therapeutic delay of weeks to months before antidepressant
activity is evident. This delay is thought to reflect neuroadaptive
changes in pre- and postsynaptic cells, including long-term
changes in gene expression and protein translation (Krishnan
andNestler, 2008). Although the cell types and precisemolecular
mechanisms mediating the efficacy of antidepressant drugs
have not been identified, neuroimaging studies have shown
that the clinical effects of antidepressant drug therapy and
deep brain stimulation correlate with increased activity in the
cerebral cortex (Drevets et al., 2008; Mayberg, 2009). Given
these observations, and the dramatic regulation of p11 in the
frontal cortex of depressed patients, we wished to determine
whether p11-expressing cells in the cerebral cortex are critically
important for antidepressant action, and to search for beneficial
adaptations that may occur in these cells in response to chronic
antidepressant treatment.
For this study, we created an S100a10 bacTRAPmouse line to
characterize p11-expressing cells and measure their responses
to antidepressant treatment (Doyle et al., 2008; Heiman et al.,
2008). We report that p11 is highly enriched in layer 5 cortico-
striatal (CStr) projection neurons, that these cells respond prefer-
entially to chronic SSRI treatment by altering serotonergic tone,
and that loss of p11 in the cortex results in the inability to respond
to an SSRI. Our data demonstrate that the beneficial actions of
antidepressant therapy can be mediated by a single cell type
in the cerebral cortex, and suggest that development of drugs
that specifically target the activity of CStr neurons can result in
improved therapies for depression.
RESULTS
An S100a10 bacTRAP Transgenic Line
Previous in situ hybridization (ISH) studies have shown that the
S100a10 gene is expressed in the cerebral cortex (Arlotta
et al., 2005; Svenningsson et al., 2006), although the cell types
expressing S100a10 in layer 5 and their position in CNS circuitry
have not been determined. To identify this cell population and
study its properties using the translating ribosome affinity
purification (TRAP) approach, bacTRAP transgenic mice were
generated using a BAC clone containing the S100a10 gene.
The EGFP-L10a ribosomal protein fusion (Heiman et al., 2008)
was engineered into the S100a10 BAC by homologous recombi-
nation in Escherichia coli (Gong et al., 2002) so that it would be
expressed under the control of S100a10 regulatory elements
(Figure 1A). S100a10 bacTRAP founder line ES691 was chosen
for further analysis because the pattern of transgene expression
reliably recapitulated endogenous expression patterns of the
S100a10 gene throughout the brain (Figure S1 available online).
In the cortex, EGFP-L10a was expressed in a laminar
pattern (Figures 1B and 1C and S1A), consistent with previous
reports (Arlotta et al., 2005; http://www.gensat.org; http://
www.brain-map.org; http://www.stjudebgem.org). Transgene
expression was primarily restricted to superficial layer 5 (layer
5a), although a few cells with low levels of EGFP-L10a expres-
sion could be found in layers 4 and 5b. EGFP-L10a expression
was localized to the soma, proximal dendrites, and the nucle-
olus, as previously described for other bacTRAP mouse lines
(Doyle et al., 2008; Heiman et al., 2008). At high magnification,
it was evident that somas of EGFP-L10a+ cells were pyramidal,
with a clear apical dendrite (Figure 1D). As shown in Figure 1E, all
EGFP+ cells were also labeled with anti-p11, and the vast
majority of p11+ cells also expressed the fusion protein. These
results confirm previous studies demonstrating laminar expres-
sion of the S100a10 gene in the cortex, identify these cells as
layer 5a pyramidal cells, and demonstrate that the ES691
bacTRAP transgenic line faithfully reproduces expression of
endogenous S100a10 in the mouse cortex.S100a10-Expressing Pyramidal Neurons Project
to the Dorsal Striatum and Contralateral Cortex
Inspection of an S100a10 EGFP transgenic reporter line (http://
www.gensat.org) revealed axons within the corpus callosum
and striatum, and no labeling in the thalamus or pyramidal tract,
suggesting that the S100a10-expressing cells project primarily
to the striatum. To determine definitively the axonal targets of
the pyramidal cells labeled in the S100a10 bacTRAP line, retro-
grade tracing experiments were performed using fluorescently-
tagged cholera toxin b subunit (CTb). These studies demonstrate
that pyramidal cells labeled in the S100a10 bacTRAP line
provide a major afferent input to the dorsal striatum (caudate
putamen [CPu]). Thus, 72 ± 5% of the cortical neurons labeled
by injecting CTb into CPu were also EGFP-L10a+ (Figures 2A
and 2C). Injections into different areas of the CPu resulted in
labeling of S100a10 neurons in diverse areas of cortex, reflecting
the topographic map of CStr projections (Figure S2D). A large
proportion of cells that were double positive for CTb and
EGFP-L10a were also found in contralateral cortex following
injections into CPu (Figure 2C), indicating that the S100a10 cells
are capable of making both ipsilateral and contralateral projec-
tions to the dorsal striatum. The laminar distribution of EGFP-
L10a+ andCTb+ substantially overlapped (Figure 2B), consistent
with previous studies demonstrating that a majority of striatally
projecting cortical neurons are present in layer 5a.
Because the CPu and nucleus accumbens (NAc) are
known to be functionally distinct, and because the majority of
cortical inputs to the NAc arise from medial prefrontal cortical
areas, we employed CTb retrograde tracing to ask whether
S100a10-expressing neurons project to the ventral striatum.
Although CTb- and EGFP-L10a-labeled cell bodies were inter-
mingled in frontal cortex, there was minimal overlap between
accumbal projecting neurons and S100a10 cells (1.9 ± 1.7%
ipsilaterally and 3.9 ± 1.4% contralaterally; Figures 2A and 2C).
Rather, medial prefrontal S100a10 cells colabeled with injections
to anteromedial CPu whereas those in lateral regions sent
projections primarily to anterolateral CPu (Figure S2 and data
not shown). We conclude that the major afferent input from the
cortex to the CPu originates in S100a10-expressing pyramidal
cells, but that direct projections from the frontal cortex to the
NAc do not arise from this cell population.
As it is common for CStr neurons to send collateral projections
to contralateral cortex, we examined whether this was the
case for S100a10 cells. When CTb was injected into somato-
sensory cortex, CTb+ commissural projecting neurons (CPNs)
were widely distributed across the cortex and showed no
laminar patterning (Figures 2A and 2B). However, we found
that 66 ± 8% of CTb+ cells in layer 5 of contralateral cortex
were also EGFP+ (Figure 2C). Although we cannot definitively
conclude that individual S100a10-expressing neurons that
project to the striatum also send collaterals to contralateral
cortex, strong support for this suggestion comes from the fact
that the majority of layer 5 cells labeled by retrograde tracing
with CTb from either the dorsal striatum or the contralateral
cortex are EGFP-L10a+.
Finally, we note that retrograde tracing from the cervical spinal
cord revealed little overlap between corticospinal tract (CST)
projection neurons in layer 5b and S100a10-expressing cellsCell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc. 1153
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Figure 1. The S100a10 bacTRAP Mouse Line Labels a Subpopulation of Pyramidal Cells in the Cerebral Cortex
(A) Schematic depicting themodification of the BAC vector containing the S100a10 gene by RecA-mediated homologous recombination in bacteria. Exons 1–3 of
the S100a10 gene are represented by black bars. (A) and (A0) refer to the homology region used for recombination. Upstream and downstream transcriptional
regulatory elements are represented by white bars on the BAC vector. The red box following the EGFP-L10a transgene represents the polyA site.
(B) Low magnification anti-EGFP IF image of EGFP-L10a transgene expression in the brain of S100a10 bacTRAP mouse. Scale bar represents 2 mm. See also
Figure S1.
(C) EGFP-L10a expression in multiple regions of neocortex. EGFP (green) and NeuN (red) staining are shown. Layers are indicated. Scale bar represents 500 mm.
(D) High magnification image of cell bodies of EGFP+ cells. Apical dendrites are indicated by double arrowheads (where visible). In cases where the apical
dendrite is out of the plane of section, single arrowheads indicate the base. Scale bar, 25 mm.
(E) Double-labeling with anti-EGFP and anti-p11 antibodies in WT (top row) and constitutive p11 KO (bottom row) in sensorimotor cortex of S100a10 bacTRAP
mice. Scale bar, 50 mm.(Figures 2B and S2B), despite the fact that long distance projec-
tion neurons of this class are known to send axon collaterals
to the striatum. Taken together, our results demonstrate that
S100a10-expressing pyramidal cells constitute a major class of
layer 5 neurons whose projections are limited to forebrain struc-
tures (Figure 2D). The fact that these neurons send afferents
specifically to medial and lateral CPu, and that they do not
provide inputs to the NAc, is interesting given the concept of
multiple, parallel, and functionally segregated pathways from
the cerebral cortex to the striatum that has emerged from rodent1154 Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc.and primate neuroanatomical studies over the last several
decades (Voorn et al., 2004).
S100a10-Expressing Cells and Glt25d2-Expressing
Cells Are Molecularly Distinct
To compare themolecular properties of a secondwell character-
ized pyramidal cell type to the S100a10 CStr cell population, we
chose Glt25d2-expressing corticopontine neurons. Glt25d2-
expressing pyramidal cells are long-distance projection neurons
that reside in layer 5b and send axons to pons, thalamus, and
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Figure 2. Retrograde Tracing Reveals Axonal Targets of S100a10-Expressing Cells
(A) Representative images from CTb injections into dorsal striatum (CPu; top row), nucleus accumbens (NAc, middle row), and contralateral cortex (bottom row).
Left panels are low magnification images of cortex with the injection site shown in inset, and right three panels are higher magnification IF images of double-
labeling with anti-EGFP and anti-CTb antibodies. Arrows indicate double-labeled cells; asterisks indicate CTb+ cells that are not colabeled with EGFP.
(B) Histogram of the depth of the cell bodies of EGFP+ cells (EGFP), and CTb+ cells projecting to CPu or spinal cord (SpC) in motor cortex (left), and CTb+
commissural projection neurons (Cortex) in sensory cortex (right).
(C) Quantification (mean ± SEM) of the number of CTb+ cells that were colabeled with EGFP following injections into CPu, NAcc, and contralateral cortex.
(D) Schematic demonstrating the projection targets of S100a10-expressing cortical projection neurons. Brain diagram was modified from Franklin and Paxinos
(2008).
See also Figure S2.spinal cord (Doyle et al., 2008; Groh et al., 2010). Their dendritic
architecture and electrophysiological properties distinguish
them fromCStr cells (Groh et al., 2010). Glt25d2 cells are present
deeper in layer 5 than S100a10 neurons in multiple areas of
cortex and cell somas of Glt25d2 cells are larger than those of
S100a10 cells (Figure S3), consistent with previous observations
(Groh et al., 2010).
The TRAP strategy allows identification of all proteins being
synthesized in any genetically targeted cell population, and alter-
ations of this translational profile in response to pharmacological
perturbations (Doyle et al., 2008; Heiman et al., 2008). To identifymoleculardistinctionsbetweenS100a10andGlt25d2-expressing
cells, we isolated polysome-bound mRNA from these cell types
andassayed global differences in gene expression usingmicroar-
rays. Because the S100a10 gene and the corresponding EGFP-
L10a bacTRAP construct are also expressed in the pia mater
and some blood vessels in the brain (Figures S4A–S4D), we
limited our analysis to a subset of 12,235 probe sets (representing
8,390genes) that areexpressedspecifically in neurons (TableS1).
As shown in Figure 3A, comparative analysis of mRNAs immuno-
precipitated (IP) from S100a10 cells versus those present in the
whole cortex (input) demonstrates selective enrichment ofCell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc. 1155
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Figure 3. S100a10 and Glt25d2 Are Molecu-
larly Distinct Cell Populations
(A) Scatter plot comparing normalized expression
values of neuronal genes (see Figure S4 and Table
S1) in S100a10 IP (x axis) or whole cortex input
(y axis). Blue dots represent individual probe sets.
Outer gray lines represent 1.5-fold enrichment in
either sample. Probe sets representing the
S100a10 gene are circled.
(B) Quantification (mean ± SEM) of expression of
control genes (Aldh1l1, Cnp, Gad1, and Slc17a7)
and previously reported BAC driver genes (Etv1
and Ntsr1, gray bars) by qRT-PCR in S100a10 IP
versus whole cortex (UB) RNA. Dotted lines mark
2-fold regulation. *p < 0.05; **p < 0.01.
(C) Scatter plot comparing normalized expression
values of CST (red dots) or CPN (blue dots)
markers (see Figure S3 and Table S2) in Glt25d2
(x axis) or S100a10 (y axis) IP samples. Outer gray
lines represent 1.5-fold enrichment in either cell
population. Probe sets representing S100a10
and Glt25d2 are indicated.
(D) qRT-PCR quantification (mean ± SEM) of the
expression of cortex layer 5 genes in S100a10 IP
compared to either Glt25d2 IP (white bars) or
whole cortex (UB, gray bars). Positive values
indicate enrichment in S100a10 IP whereas
negative values indicate enrichment in UB or
Glt25d2 IP. Dotted lines mark 2-fold regulation.
p < 0.05 for all genes shown.
(E–J) In situ hybridizations showing expression
patterns in cortex of genes enriched in S100a10
(E–I) or Glt25d2 (J) cells. All images are from the
Allen Brain Atlas.S100a10 probe sets in the IP (7.5- and 5.9-fold). Quantitative RT-
PCR (qRT-PCR) of TRAP RNA showed that mRNA for the vesic-
ular glutamate transporter, Slc17a7, was expressed (although
not enriched compared to neighboring cells), confirming that the
S100a10 cells are indeed excitatory neurons (Figure 3B). In
contrast, mRNAs specific to astrocytes (Aldh1l1), oligodendro-
cytes (Cnp), and GABAergic interneurons (Gad1) were expressed
at very low levels compared to the input (Figure 3B). mRNA for
genes known to label other pyramidal cell types (Doyle et al.,
2008), including layer 6 corticothalamic (Ntsr1), a subpopulation
of layer 5 CStr (Etv1), and Glt25d2 were not enriched in IP
mRNA (Figures 3B and 3D), suggesting that the S100a10 cells
are a unique, previously uncharacterized cell population.
To assess whether other genes enriched in the S100a10 IP
distinguish these cells from Glt25d2-expressing pyramidal cells,1156 Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc.mRNAs purified from these two cell types
using the TRAP protocol were compared.
This analysis resulted in identification
of 1,112 differentially expressed mRNAs
(data not shown). Genes previously
shown to be expressed in CST projection
neurons were more highly enriched in the
Glt25d2 cells, whereas those demon-
strated to be expressed in CPNs in
cortical layer 5 were preferentially ex-pressed in the S100a10 cells (Figure 3C and Table S2). To
demonstrate that the bacTRAP data collected from the
S100a10 and Glt25d2 pyramidal cell populations provide cell
type specific information even for those genes that have previ-
ously been identified as expressed in layer 5 of the cerebral
cortex, and to identify useful additional markers for CStr
neurons, we compared our data with genes annotated as specif-
ically expressed in layer 5 by the Allen Brain Atlas. Although
the ISH data demonstrate laminar expression in layer 5 for
each of the six examples shown (Figures 3E–3J), comparative
analysis of the translational profiles of S100a10 and Glt25d2
pyramidal cells identify Akap12, Depdc6, D6Wsu176e, Dexi,
and Emb as specifically expressed in CStr cells, and
D330050I23Rik as enriched in corticopontine neurons (Fig-
ure 3D). These results demonstrate the value of bacTRAP
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Figure 4. Cell Type-Specific Molecular Responses to SSRI Treatment
(A) The level of p11 mRNA was quantified by ISH and expressed as percent of control (mean ± SEM). Representative images are shown below the graph.
*p < 0.05.
(B) Scatter plot comparing normalized expression values of FLX- (x axis) or VEH (y axis)-treated cortex IP samples from S100a10 (left) or Glt25d2 (right) bacTRAP
mice. Dots represent probe sets that are significantly increased (red) or decreased (green) >1.4-fold by drug treatment (see Table S3). Outer gray lines represent
1.4-fold enrichment in either sample.
(C) Quantification of Htr expression following chronic FLX in S100a10 and Glt25d2 cells by qRT-PCR (mean ± SEM). Positive values indicate upregulation and
negative values indicate downregulation by FLX. Dotted lines show a 2-fold change in either direction. *p < 0.05.
(D) Quantification of Htr expression following chronic FLX in whole cortex by qRT-PCR (mean ± SEM).
See also Figure S4.data for definitively identifying the specific cell type expressing
a gene of interest and for determining the distinguishing molec-
ular characteristics of closely related cell types, as well as illus-
trate the utility of ISH databases as tools for validation of
bacTRAP data sets.
S100a10 Corticostriatal Neurons Respond Specifically
to Antidepressant Treatment
Given human neuroimaging studies implicating CStr circuits in
the response to antidepressants (Drevets et al., 2008), previous
studies demonstrating the induction of p11 in the cerebral cortex
by antidepressants and electroconvulsive therapy (Svennings-
son et al., 2006; Warner-Schmidt et al., 2010), and the present
demonstration that S100a10-expressing cells provide a major
and specific pathway for communication between the cortex
and dorsal striatum, we were interested in examining the possi-
bility that these cells respond preferentially and specifically to
antidepressant treatment. We chose the selective serotonin
reuptake inhibitor (SSRI) fluoxetine (FLX) because it is one of
the most highly prescribed antidepressants and is known to
have antidepressant activity in rodent models of depression(Cryan et al., 2005; Dulawa et al., 2004). It was previously
reported that chronic administration of tricyclic antidepressants
imipramine or tranylcypromine increases the amount of p11 in
the cortex inmice (Svenningsson et al., 2006). To assesswhether
FLX had a similar effect, we treated wild-type (WT) mice with
FLX or saline for 14 days, and measured levels of p11 mRNA in
the cortex by ISH. As expected, p11 expression increased
25% in response to FLX (Figure 4A), confirming the previous
observation that p11 expression in cortex is sensitive to antide-
pressant action (Svenningsson et al., 2006).
To identify long-term neuroadaptations that occur in response
to SSRI treatment, we administered FLX (0.167mg/ml) or vehicle
(VEH) to S100a10 and Glt25d2 bacTRAP mice in their drinking
water for 15–18 days. No change in the distribution of cells
expressing EGFP-L10a occurred in either bacTRAP line in
response to treatment (data not shown). Polysome-bound RNA
from the cortex of each line was collected using TRAP, and
microarray analysis was used to examine the effect of chronic
FLX on the profile of proteins being synthesized by each cell
type. Sixty-two genes (65 probe sets) were differentially regu-
lated by FLX in the S100a10 cells, as opposed to only four inCell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc. 1157
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Figure 5. Molecular Changes Are Depen-
dent on p11 Expression
(A) Anti-EGFP IF image of EGFP-L10a expression
in constitutive p11 KO mice crossed to the
S100a10 bacTRAP line. See Figure S5 for further
anatomical analysis.
(B) Quantification of Htr expression in IP RNA from
S100a10 bacTRAP/p11 KO relative to WT cortex
by qRT-PCR (mean ± SEM). Dotted line indicates
a 2-fold change. Negative values indicate
downregulation in KO compared to WT. *p < 0.05,
**p < 0.01.
(C) Scatter plot comparing normalized expression
values of FLX- (x axis) or VEH (y axis)-treated
cortex IP samples from S100a10 bacTRAP/p11
KO mice. Dots represent probe sets that are
significantly increased (red) or decreased (green)
>1.4-fold by drug treatment in WT cortex (see
Figure 4B and Table S3). Outer gray lines represent
1.4-fold enrichment in either sample.
(D) Quantification of Htr expression following
chronic FLX in S100a10 bacTRAP/p11 KO cells
by qRT-PCR (mean ± SEM). Positive values
indicate upregulation and negative values
indicate downregulation by FLX treatment. Dotted
lines indicate a 2-fold change in either direction.
*p < 0.05.the Glt25d2 cells (Figure 4B and Table S3). These data confirmed
the hypothesis that the S100a10 (and thus p11)-expressing cells
are preferentially sensitive to antidepressant treatment, and
suggest that this population of CStr cells might play an important
role in antidepressant therapy.
Given the facts that p11modulates Htr function (Svenningsson
et al., 2006; Warner-Schmidt et al., 2009), and that chronic
treatment with SSRIs results in elevated levels of serotonin in
the nervous system, we asked whether the response of
S100a10-expressing cells to FLX included long-term changes
in the expression of Htrs. We restricted our analysis to Htrs
expressed in cortical neurons (see Table S1). As shown in Fig-
ure 4C, a dramatic and specific increase in Htr4 mRNA
(16-fold) occurred in S100a10 cells following chronic FLX treat-
ment. Elevated Htr4 expression was not observed in Glt25d2
neurons and no increases in the expression of other Htr subtypes
were observed in either cell type. Further, this increase in Htr4
expression was not detectable in whole cortex (input) samples
(Figure 4D). Taken together, our data both demonstrate that layer
5 CStr projection neurons are highly responsive to antidepres-
sant treatment, and suggest that the induction of Htr4 expres-
sion in this critical cell population may play an important role in
restoring the balance between cortical and striatal activity that
occurs in response to SSRIs.
Serotonin Receptors Are Dysregulated in
S100a10-Expressing Cells in p11 Null Mutant Mice
p11 directly interacts with multiple Htrs, and its loss leads to
reduced responses of cortical cells to serotonin at striatal
synapses (Svenningsson et al., 2006). To determine whether
p11 is involved in the molecular adaptations that we have1158 Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc.observed in CStr neurons in response to SSRIs, we crossed
S100a10 bacTRAP mice with p11 knockout (KO) animals
(Svenningsson et al., 2006) to obtain animals (S100a10
bacTRAP/p11KO) in which the molecular consequences of p11
deletion could be assessed in CStr pyramidal cells. EGFP-
L10a transgene expression was not significantly altered in the
cortex of KO mice (Figures 1E and 5A), and retrograde tracing
revealed that EGFP-expressing cells still accounted for amajority
of projections to CPu and contralateral cortex (Figure S5A). As
shown in Figure 5B, deletion of p11 resulted in severe dysregu-
lation of Htrs in these neurons. Htrs 1a, 1b, 2c, 5a, and 7 were all
significantly downregulated in the KOs. No significant change
was observed in the translation of Htr1d or Htr4, both of which
bind directly to p11. However, given previous studies demon-
strating that the cell surface expression of Htr1b and Htr4 is
critically dependent on p11 (Svenningsson et al., 2006;
Warner-Schmidt et al., 2009), we expect that signaling through
these receptors is also reduced. Taken together, our data
suggest that deletion of p11 results in a loss of serotonergic
tone in CStr pyramidal cells.
We next tested whether the alterations in Htr expression in
S100a10 cortical neurons in p11 KOs resulted in dampened
responses to FLX. S100a10 bacTRAP/p11KO mice received
chronic administration of FLX or VEH as described above, and
translational profiles from these cells were assayed on microar-
rays. As shown in Figure 5C, p11 KO animals failed to show the
robust response to FLX observed in S100a10 CStr neurons.
Thus, the majority of genes shown to be significantly regulated
in the S100a10 cells of WT animals were no longer regulated
by FLX in the p11 KO, and the induction of Htr4 noted in WT cells
was significantly blunted (Figure 5D; p < 0.05, Student’s t test).
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Figure 6. Cortical Expression of p11 Is Required
for Behavioral Responses to Chronic SSRI
Administration
(A) Anti-p11 IF in brain sections from floxed p11 mice (WT,
top row) and Emx1/p11KO mice (bottom row) from layer 5
of sensorimotor cortex (left panels), striatum (center), or
dentate gyrus (right). Inset shows anti-NeuN staining from
the same field. Asterisks label p11-positive cells.
(B) Bar graph representing the effect of chronic FLX
treatment on the latency to feed in WT and Emx1/p11 KO
(Cortex KO) mice in the novelty NSF paradigm (mean ±
SEM). **p < 0.01.
(C) Bar graph representing the effect of chronic FLX
treatment on immobility in WT and Emx1/p11 KO (Cortex
KO) mice in TST (mean ± SEM). *p < 0.05.
(D) Bar graph representing thigmotaxis in an open field in
WT or Emx1/p11 KO (Cortex KO) mice (mean ± SEM).
(E) Bar graph representing sucrose preference in WT or
Emx1/p11 KO (Cortex KO) mice (mean ± SEM). Dotted line
indicates no preference.
See also Figure S5.We conclude that the actions of SSRIs on S100a10 CStr projec-
tion neurons are critically dependent on p11.
Behavioral Responses to Antidepressants Depend on
the Presence of p11 in the Cerebral Cortex
Given our bacTRAP molecular phenotyping data establishing
S100a10 CStr pyramidal cells as strongly and specifically
responsive to chronic SSRI treatment, and our demonstration
that these cells provide the majority of afferents to the dorsal
striatum from the cortex, we were interested in testing the role
of S100a10 cortical neurons in the therapeutic actions of antide-Cell 149, 11pressants. Because CStr cells in p11 KOs failed
to show molecular responses to FLX and have
altered expression of Htrs, we generated
cortex-specific p11 KO animals (Emx1/p11KO)
to assess the functional consequences of loss
of these adaptations on behavior. Immunohisto-
chemistry was employed to confirm the loss of
p11 from the cortex, and its continued expres-
sion in the striatum and in other subcortical sites
(Figure 6A; data not shown).
We employed the novelty suppressed feeding
(NSF) paradigm and the tail suspension test
(TST) to assess the therapeutic actions of
chronic FLX in Emx1/p11KO mice. In NSF,
food-deprived mice are placed in an open field
that contains food in the center. The mice
must decide to approach and consume the
food, or avoid the novel environment. Animals
treated with antidepressants for several weeks
before testing consistently exhibit shorter
feeding latencies than those that received acute
or no treatment, making NSF a valuable assay
for evaluating responses to chronic antidepres-
sant administration (Dulawa and Hen, 2005). We
found that Emx1/p11KO mice failed to exhibit
behavioral responses to chronic FLX treatmentin NSF (Figure 6B). WT mice (carrying the floxed p11 allele but
not Cre) showed a significantly decreased latency to feed (436
± 36 s) following chronic FLX administration compared to VEH-
treated controls (561 ± 25 s). In contrast, there was no difference
in latency between VEH and FLX administration (523 ± 32 versus
469 ± 41 s) in Emx1/p11KO mice. VEH-treated Emx1/p11KOs
showed no difference in baseline anxiety (as measured by
latency to feed) compared to WT mice (Figure 6B, white bars).
Further supporting the conclusion that the behavioral differences
in the NSF test likely reflect an inability of the cortex-specific KOs
to respond to drug treatment rather than a change in generalized52–1163, May 25, 2012 ª2012 Elsevier Inc. 1159
anxiety, mice of all genotypes displayed no difference in thigmo-
taxis in an open field test.
We also tested Emx1/p11 KO mice in the TST, which is
a classic behavioral test widely employed to screen antidepres-
sant efficacy in mice (Cryan et al., 2005). The TST measures the
timemice spend immobile while being suspended by their tail, an
inescapable stress. Following chronic FLX treatment, WT mice
exhibited a significant reduction (20%) in immobility in the
TST and this effect was abolished in Emx1/p11KOs (Figure 6C).
There was no difference between genotypes in locomotor
activity (Figure S5B), and importantly there was also no indica-
tion of a depressive-like effect in Emx1/p11 KO on immobility
in the TST (Figure 6C, white bars), or anhedonia in the sucrose
preference test (Figure 6E). These data further support the notion
that the behavioral phenotype of Emx1/p11KO mice lies in their
lack of response to FLX treatment and not to an elevated depres-
sive-like state.
Emx1/p11KOmice also failed to display a behavioral response
to chronic FLX in the forced swim test (FST; Figure S5C). WT
animals showed the expected decrease in immobility following
chronic FLX treatment, but it did not reach statistical significance
(p = 0.08). This is likely due to genetic background, because our
mice were backcrossed onto the C57BL/6 strain and it has been
shown that chronic, but not acute, FLX treatment in drinking
water reduced immobility in the FST in BALB/c mice but not
C57BL/6 mice (Dulawa et al., 2004). We conclude that proper
function of S100a10 CStr pyramidal cells is required for normal
behavioral responses to chronic antidepressant treatment.
DISCUSSION
Human neuroimaging studies have consistently demonstrated
alterations in cortical activity in depressed patients and normali-
zation of this activity in response to antidepressants, although
neither the cell types altered in response to treatment nor the
nature of the neuroadaptations that occur in these cell types
have been identified. In this study, we show that CStr projection
neurons expressing S100a10 (p11) are essential for both the
molecular andbehavioral responses to theSSRIFLX.Wedemon-
strate that S100a10 pyramidal cells project primarily to the dorsal
striatum and contralateral cortex, and that they experience long-
term adaptive changes in response to chronic administration of
FLX that do not occur in other layer 5 projection neurons. These
adaptations require p11 and include the induction of Htr4
receptor expression. Finally, we show that deletion of p11 in
these cells abolishes behavioral responses to FLX, but does not
lead to a depressive-like phenotype. Our data identify S100a10
CStr neurons as essential for the actions of SSRI antidepres-
sants, reveal specific molecular adaptations that occur in these
cells in response to chronic treatment, and suggest that modula-
tion of serotonergic tone in this single cortical cell population can
result in effective antidepressant therapy.
Impact of bacTRAP Translational Profiling
of Disease-Relevant Cell Types
Molecular phenotyping of cell types that comprise the neural
circuits underlying pathological neuropsychiatric conditions
and their responses to therapy provides one avenue for develop-1160 Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc.ment of more specific and effective treatments. Until recently,
the histological complexity of the CNS has provided a barrier
for such studies, especially in the cerebral cortex where few
molecular markers exist to distinguish between subpopulations
of morphologically similar pyramidal cells. In this study, we
took advantage of the discovery that p11 is regulated in the
cortex following antidepressant treatment (Svenningsson et al.,
2006) and of the recently developed bacTRAP approach for
translational profiling of specific CNS cell types (Doyle et al.,
2008; Heiman et al., 2008) to study long-term changes that occur
in specific cortical neuron populations in response to antidepres-
sants. Our results demonstrate that bacTRAP translational
profiling can be used to identify cell types that respond to thera-
peutic drugs, and provide a first illustration that those cells most
responsive to treatment may also participate in the therapeutic
actions of the drug. It will be of great interest to employ this
strategy in other mouse models of psychiatric and neurological
disease to explore further the relationship between molecular
phenotype and cellular function in the setting of complex, circuit
based disorders.
Our data argue strongly that the specific molecular changes
that occur in relevant cell types in the context of effective treat-
ment of disease may provide critical insights into mechanisms
that determine therapeutic efficacy. For example, we have
shown here that chronic treatment with FLX results in the specific
induction of Htr4 expression in S100a10 CStr pyramidal cells,
and that loss of p11 causes both a decrease in the expression
of Htrs in this cell type and a failure to respond behaviorally to
antidepressants. The induction of Htr4 expression is consistent
with previous studies showing that Htr4 agonists have antide-
pressant effects (Lucas et al., 2007) that are dependent on p11
expression (Warner-Schmidt et al., 2009). This suggests the
specific hypothesis that the increase of Htr4 expression
following chronic FLX treatment enhances the sensitivity of
CStr neurons to the elevated serotonin levels, thereby increasing
outflow from the cerebral cortex to the striatum and contributing
to the efficacy of antidepressants. The fact that the loss of p11
from these cells resulted in a downregulation of many Htrs
suggests a wider impact of p11 on serotonergic tone. Although
additional experimentation is needed to test this hypothesis,
our data strongly argue that the information obtained from
TRAP profiling of individual cell types in mouse models of
disease can significantly advance our understanding of molec-
ular and cellular mechanisms of disease.
Corticostriatal Neurocircuitry Mediating
Antidepressant Responses
A confluence of evidence has emerged from studies as diverse
as human neuroimaging (Drevets et al., 2008; Mayberg et al.,
1999) and immediate early gene transcription (Covington et al.,
2010) to implicate altered activity in several brain areas in
depression. These studies form the basis of our current under-
standing of depression, in which mood is governed by a distrib-
uted brain circuit that does not function normally in depressed
individuals (Ressler and Mayberg, 2007). Given this under-
standing, how is it that the molecular adaptations that occur in
a single circuit element (S100a10 CStr projection neurons) can
be so important for the antidepressant activity of SSRIs? Our
data identify several factors that may help to answer this query.
First, S100a10 pyramidal cells occupy a critical position in the
mood circuitry. We have shown by retrograde tracing that this
cell population provides a major conduit for communication
between the cortex and the dorsal striatum. Although early
studies emphasized a role for the ventral striatum in reward pro-
cessing and depression, recent structural and functional imaging
studies have revealed that the dorsal striatum is both active
during reward related tasks and altered in MDD (Delgado,
2007; Pizzagalli et al., 2009). In particular, reduced prediction
error signals in both the bilateral caudate and the NAc correlate
with increased anhedonia (a core feature of MDD) in depressed
subjects (Gradin et al., 2011). In addition, MDD subjects with
elevated anhedonic symptoms or late-onset depression showed
a reduced caudate volume (Krishnan et al., 1992; Pizzagalli et al.,
2009). It is possible that S100a10 CStr cells projecting to dorso-
medial striatum (DMS) underlie antidepressant responses. This
idea is supported by a growing body of evidence demonstrating
that the DMS plays a significant role in reward learning and moti-
vated behavior (Voorn et al., 2004).
The adaptations that occur in this cell type in response to FLX,
including the increase in Htr4 expression, occur specifically in
S100a10 CStr cells. Thus, we were not able to detect these
changes in TRAP data from Glt25d2 corticopontine neurons or
in data collected fromwhole cortex samples. These results high-
light the unique biochemical properties of distinct classes of
pyramidal cells, and confirm our previous demonstration that
the genome wide pharmacokinetic responses of even closely
related cell types can vary dramatically (Heiman et al., 2008).
Finally, it is important to emphasize that we chose to analyze
p11-expressing cortical neurons because previous studies had
shown that this protein is expressed in a laminar pattern in the
cortex, and that its expression in cortex is reduced in depressed
individuals and restored in response to treatment (Anisman et al.,
2008; Svenningsson et al., 2006). We report here that p11 is
required for the molecular adaptations seen in CStr cells in
response to an SSRI, and that loss of p11 expression in the
cortex abolishes behavioral responses to the SSRI FLX.
Although the large number of distinct serotonin receptors and
their broad distribution across the nervous system (and
periphery) suggest that serotonin elicits a variety of responses
in vivo, it seems possible that effective long-term, functional
adaptation to SSRIs may require a constellation of factors
present only in S100a10 cortical neurons.
Our datademonstrate that the beneficial actions of SSRI antide-
pressant therapy may be mediated by a single cell type in the
cerebral cortex, and suggest that development of drugs that
specifically target the activity of CStr neurons may result in
improved therapies for depression. However, it is important to
note that our results do not predict that the pathophysiological
changes that elicit depression occur in this cell type, or thatmodu-
lation of other critical cell types might not provide equally effective
therapies. The observation that deletion of p11 in the cerebral
cortex results in a lack of responsiveness to FLX but does not elicit
depressive-like or anxiety behaviors strongly suggests that loss of
p11 in other cell typesmust be involved in generation of the behav-
ioral phenotypesevident in constitutive p11KOmice. Although the
separation of the anatomical locations responsible for generationof the behavioral phenotypes from those governing treatment
responses in this animal model of depression may need clarifica-
tion, we believe that such a dichotomy is typical of complex
circuit-based disorders. For example, deep brain stimulation
studies of Parkinson’s disease have shown that even circuits
that are irreversibly altered as a result of neurodegeneration can
be phenotypically normalized by stimulation of circuit elements
that are not lost as a result of the pathophysiology of the
disease (Limousin and Martinez-Torres, 2008). Given the genetic
complexity of MDD and the circuitry that is involved in the regula-
tion of mood, we expect that the causes of MDDwill alter function
atmany points in themood circuitry. However, the identification of
a single cell type in the cerebral cortex that is both positioned to
normalize activity between cortical and subcortical sites, and
that is required for the response to SSRI antidepressants, is an
exciting step forward in the march toward development of more
effective treatments for depression.
EXPERIMENTAL PROCEDURES
Animals and Drug Treatments
All procedures involving animals were approved by the Rockefeller University
Institutional Animal Care and Use Committee and were in accordance with the
National Institutes of Health guidelines. The Glt25d2 bacTRAP mice, constitu-
tive p11 KOmice, and Snap25 bacTRAPmice were generated and maintained
at Rockefeller University and have been described previously (Doyle et al.,
2008; Svenningsson et al., 2006). The S100a10 bacTRAP transgenic mouse
line was generated by modifying a BAC clone containing the S100a10 gene
to insert an EGFP-L10a fusion protein into the translation start site, and the
modified BAC was purified and used for transgenesis as described previously
(Gong et al., 2002). See Extended Experimental Procedures for details.
Cortex-specific p11 KO mice were generated by breeding floxed p11 mice
(Warner-Schmidt et al., 2011) with Emx1-Cre mice purchased from The Jack-
son Laboratory (Stock 005628). All mice were maintained on a 12-hr light/dark
cycle and given ad libitum access to food and water. For chronic drug treat-
ments, mice were housed one to two per cage and a FLX (0.167 mg/ml)/
saccharine (1%) mixture or saccharine alone (VEH) was administered in the
drinking water for 15–18 days and replaced with fresh solution every 3–4 days.
Retrograde Labeling and Immunohistochemistry
Alexa-555-conjugated cholera toxin b-subunit (Invitrogen) was stereotaxically
injected into adult (8–12 weeks old) transgenic mice under ketamine/xylazine
(100/10 mg/kg) anesthesia as described in Supplemental Information. Quanti-
fication of double-labeled cells and cell depth was done using Image J (NIH) as
detailed in Extended Experimental Procedures.
Immunohistochemistry and In Situ Hybridization
Tissue was prepared as described in Extended Experimental Procedures.
Immunofluorescent staining was carried out on 35-mm thick sections using
chicken anti-GFP (1:2,000, Abcam), mouse anti-EGFP (1:500; Heiman et al.,
2008), rabbit anti-CTb (1:1,000, Abcam), goat anti-S100a10 (1:200, R&D
Systems), and/or mouse anti-NeuN (1:1,000, Millipore) followed by Alexa-fluor
conjugated secondary antibodies (Invitrogen). All sections were imaged on
a Zeiss LSM700 confocal microscope.
S100a10 (p11) in situ hybridization was performed as described previously
(Warner-Schmidt et al., 2010) and in Extended Experimental Procedures.
Translating Ribosome Affinity Purification
Three male mice were pooled for each sample and three biological replicates
were collected for each condition. All polysome purifications and mRNA
extractions were carried out as described previously (Heiman et al., 2008)
and in Extended Experimental Procedures. RNA quantity was measured
with a Nanodrop 1000 spectrophotometer and quality was assayed on an
Agilent 2100 Bioanalyzer.Cell 149, 1152–1163, May 25, 2012 ª2012 Elsevier Inc. 1161
Microarray Analysis
For microarrays, RNA was amplified and labeled using the GeneChip Expres-
sion 30 Amplification 2-Cycle cDNA Synthesis Kit (Affymetrix) and hybridized to
GeneChip Mouse Genome 430 2.0 microarrays (Affymetrix) according to
manufacturers’ protocols. CEL files were imported into GeneSpring GX 7.3.1
and preprocessed with the GCRMA algorithm. For each experiment, data
were filtered to remove probe sets with low intensities (normalized expression
<50 in at least one condition) and those identified as background (Doyle et al.,
2008). Only probe sets expressed in neuronal cells were used for analysis (see
Supplemental Information). Differentially expressed genes were identified by
performing a moderated t test (Smyth, 2004) as described in Extended Exper-
imental Procedures. The p values were adjusted for multiple hypothesis
testing, controlling the false discovery rate with the Benjamini-Hochberg
procedure. Only genes with an FDR < 0.05 (5%) and a fold change > 1.4
were used for analyses. MIAME-compliant raw data are available from Gene
Expression Omnibus with accession number GSE35766.
Quantitative RT-PCR
cDNA was synthesized using the WT-Ovation RNA Amplification kit (NuGEN
Technologies) according to manufacturer’s protocol. For Htrs, PCR was
carried out in an Applied Biosystems StepOnePlus RT-PCR System using
TaqMan expression assays. All other reactions were performed in a Bio-Rad
iQ5 Multicolor RT-PCR Detection System using the SYBR green method
(BioRad). Data were normalized to b-actin and relative expression changes
between conditions were calculated by the comparative CT (2
DDCT) method.
Student’s t test was used for all statistical analyses. Detailed methods are
provided in Extended Experimental Procedures.
Behavioral Analysis
Detailed descriptions of all behavioral methods can be found in Extended
Experimental Procedures. NSF was performed exactly as described (Egeland
et al., 2010) and the tail suspension test, forced swim, sucrose preference, and
open field were performed as described previously (Warner-Schmidt et al.,
2009). Statistical comparisons were made by ANOVA using Prism 5 software
(GraphPad). In experiments comprised of more than two groups, data were
first analyzed by two-way ANOVA followed by post hoc Bonferroni test.
Statistical significance was set at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at
doi:10.1016/j.cell.2012.03.038.
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